申请人:FerroKin BioSciences, Inc.
公开号:US20130225645A1
公开(公告)日:2013-08-29
The present invention provides, among other things, effective oral formulations based on desazadesferrithiocin polyether (DADFT-PE) analogues, salts and polymorphs thereof, as well as their application for treatment of metal overload, in particular, iron overload, and associated diseases, disorders and conditions.
本发明提供了基于去氮去硫铁聚醚(DADFT-PE)类似物、盐和多晶形式的有效口服制剂,以及它们用于治疗金属超载,特别是铁超载以及相关疾病、疾病和病状的应用。